SpringWorks Therapeutics Inc

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in applying a precision medicine approach to acquiring, developing and commercializing medicines. It focuses on developing drugs for underserved patient populations suffering from devastating rare diseases and cancer. Its pipeline include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SpringWorks reports robust Q1 revenue, poised for patient-centric growth

SpringWorks Therapeutics demonstrated strong financial performance and market acceptance for OGSIVEO in Q1 2024.
The company's focus on patient-centric care and pipeline advancement positions them well for future growth and innovation.
While facing challenges in market competition and regulatory landscape, SpringWorks has opportunities for expansion and diversification.

SpringWorks reports robust Q2 earnings, focuses on expanding treatments

SpringWorks Therapeutics delivered strong financial performance in Q2 2024, driven by $40.2 million in net product revenue for OGSIVEO.
The company's focus on expanding OGSIVEO reach, advancing mirdametinib, and developing its emerging portfolio underscores its commitment to innovation.
While facing challenges such as rising operating expenses, SpringWorks remains well-positioned with a healthy cash reserve to pursue growth opportunities.
Strategically navigating challenges and capitalizing on opportunities will be crucial for SpringWorks to sustain its momentum and drive future success.

SpringWorks Therapeutics reports robust Q3 performance and eyes growth opportunities

SpringWorks Therapeutics demonstrates strong financial performance, a solid balance sheet, and positive market reception for their products. While regulatory hurdles exist, opportunities for growth through new approvals and expanded patient populations present promising prospects for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. All of the shares in the offering will be sold by SpringWorks. In addition, SpringWorks expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock in the offering.

SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock

The FDA approves SpringWorks' (SWTX) Ogsiveo (nirogacestat) for the treatment of adult patients with desmoid tumors. Shares rise.

SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug

STAMFORD, Conn., Nov. 29, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference, taking place in Miami, Florida on Thursday, November 30, 2023 at 8:45 a.m. ET.

SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Shares of SpringWorks Therapeutics (SWTX) soared over 18% Tuesday after the Food and Drug Administration (FDA) gave its approval for the use of its pill to treat adults with non-cancerous growths in their connective tissue.

SpringWorks Therapeutics Shares Skyrocket on FDA Approval of Desmoid Tumor Drug

SpringWorks Therapeutics Inc. shares SWTX jumped more than 9% premarket on Tuesday after the company got the first U.S. regulatory approval for a drug targeting a rare type of non-cancerous but aggressive tumors.

SpringWorks Therapeutics' stock jumps after FDA approves first treatment for rare type of aggressive tumors

SpringWorks Therapeutics (NASDAQ: SWTX) stock price bounced back in the overnight session after major developments in the company. The shares jumped by over 16% to $24.10, which was much higher than its closing price of $20.77.

As the SpringWorks (SWTX) stock price surges, is it a good buy?

– Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain, physical functioning and overall quality of life –

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

The U.S. health regulator on Monday approved SpringWorks Therapeutics' drug for treating adult patients with desmoid tumors, making it the first approved treatment for this type of non-cancerous soft-tissue growth.

US FDA approves SpringWorks Therapeutics' non-cancerous tumor treatment

SpringWorks (SWTX) posts encouraging data from phase IIb study on its MEK inhibitor, mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas. Stock falls.

SpringWorks (SWTX) Falls Despite Positive Mirdametinib Study Data

– Confirmed objective response rate of 52% in pediatric patients and 41% in adult patients, as assessed by Blinded Independent Central Review –

SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN

SpringWorks Therapeutics' lead candidate, Nirogacestat, for treating Desmoid tumors, is coming up for an FDA decision - PDUFA date - on 27 November. I believe that an FDA approval for Nirogacestat in Desmoid tumors is more likely than not and discuss why I think so. I discuss Nirogacestat in detail because I think the value of this asset alone exceeds the current market value of the company.

SpringWorks Therapeutics: How A Likely FDA Approval Can Kickstart The Stock's Repricing Potential

– PDUFA target action date for nirogacestat NDA in adults with desmoid tumors remains set for November 27, 2023 –

SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

- Nirogacestat Treatment Demonstrated Rapid and Sustained Improvements in Functional Status Compared to Placebo Across Multiple Assessment Tools -

SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting

STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Tai-An Lin, Ph.D., as its Chief Scientific Officer. Dr. Lin brings more than 25 years of biotechnology and global pharmaceutical experience in advancing drug discovery programs from target identification through early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology.

SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer

– Presented additional Phase 3 DeFi data at ASCO demonstrating clinically significant reductions in pain and substantial reductions in tumor volume and T2 hyperintensity with nirogacestat treatment –

SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Today we revisit SpringWorks Therapeutics, Inc. for the first time in nearly a year. The company's primary drug asset is on the cusp of garnering SpringWorks' first FDA approval for a rare affliction. An updated investment analysis follows in the paragraphs below.

SpringWorks Therapeutics: FDA Decision Date Ahead

STAMFORD, Conn., June 07, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA on Monday, June 12, 2023 beginning at 11:20 a.m. PT / 2:20 p.m. ET.

SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

The U.S. Food and Drug Administration (FDA) has extended its decision for SpringWorks Therapeutics Inc's tumor treatment by three months as the health regulator needs more time to review additional data, the company said on Monday.

US FDA delays decision on SpringWorks Therapeutics' tumor treatment

FDA Extending PDUFA Date by Three Months to Allow More Time to Complete Their Review; New PDUFA Date Set to November 27, 2023 FDA Extending PDUFA Date by Three Months to Allow More Time to Complete Their Review; New PDUFA Date Set to November 27, 2023

SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA

STAMFORD, Conn., May 30, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it has achieved full enrollment in its Phase 2 trial evaluating nirogacestat, an investigational gamma secretase inhibitor, as a monotherapy in patients with recurrent ovarian granulosa cell tumors (OvGCT). SpringWorks expects to report initial data from the trial in 2024.

SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

- Nirogacestat Treatment Demonstrated Rapid, Sustained and Consistent Reductions in Pain Compared to Placebo Using Multiple Assessment Tools -

SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting

STAMFORD, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the virtual TD Cowen 4th Annual Oncology Innovation Summit on Wednesday, May 31, 2023 beginning at 1:00 p.m. ET.

SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit

STAMFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that data from two collaborator-sponsored clinical studies evaluating nirogacestat, an investigational oral gamma secretase inhibitor, in combination with B-cell maturation agent (BCMA) therapies in patients with relapsed or refractory multiple myeloma (RRMM) will be presented at the European Hematology Association (EHA) 2023 Congress, taking place in Frankfurt, Germany from June 8-11, 2023. Updated clinical data from the Phase 1/2 study sponsored by GSK plc (LSE/NYSE: GSK) evaluating nirogacestat in combination with low-dose belamaf (belantamab mafodotin-blmf), GSK's antibody-drug conjugate targeting BCMA, in patients with RRMM will be presented in a poster presentation. In addition, new data from the Phase 1b clinical trial sponsored by Janssen Research & Development, LLC (Janssen) evaluating nirogacestat in combination with teclistamab, Janssen's bispecific antibody targeting BCMA and CD3, will be presented in an oral presentation.

SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress

– NDA for Nirogacestat in Adults with Desmoid Tumors Accepted by the FDA and Granted Priority Review; PDUFA Action Date Set for August 27, 2023 –

SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

STAMFORD, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Bank of America Securities 2023 Health Care Conference on Tuesday, May 9, 2023 beginning at 11:20 a.m. PT (2:20 p.m. ET).

News for SpringWorks Therapeutics Inc Stock (SWTX)